This role will lead the CLL indication across all lifecycle stages, with a strong focus on driving the transformation of the treatment paradigm, maximizing the value of Calquence, and ensuring best-in-class execution across markets.
Base: 231,989 - 347,983; Bonus/Equity: Short-term incentive bonus, equity-based long-term incentive; Benefits: 401(k) plan, paid vacation and holidays, paid leaves, health benefits
Must-have
Nice-to-have
Not specified